Innate Pharma S.A. (EPA:IPH)
Market Cap | 176.57M |
Revenue (ttm) | 20.12M |
Net Income (ttm) | -49.47M |
Shares Out | 92.16M |
EPS (ttm) | -0.61 |
PE Ratio | n/a |
Forward PE | 2.60 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 56,347 |
Average Volume | 77,670 |
Open | 1.912 |
Previous Close | 1.916 |
Day's Range | 1.890 - 1.922 |
52-Week Range | 1.330 - 2.640 |
Beta | 0.98 |
RSI | 48.25 |
Earnings Date | Sep 17, 2025 |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]
Financial Performance
In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.
Financial StatementsNews

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...

Outcome of Innate Pharma's 2025 Annual General Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma S.A. 2025 Q1 - Results - Earnings Call Presentation
Innate Pharma S.A. reports Q1 results
Innate Pharma reports Q1 results

Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the q...

Innate Pharma announces conference call and webcast for Q1 2025 business update
MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.

Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registra...

Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel a...

Innate Pharma Announces €15M Investment by Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscri...

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Coll...

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma proposes to its shareholders to transform its corporate governance structure into a board of directors and to change its composition.

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to hold its Annual General Meeting of shareholders on May 22, 2025.

Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to participate in the 2025 Stifel Virtual Targeted Oncology Forum.
Innate Pharma S.A. (IPHA) Q4 2024 Earnings Call Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2024 Earnings Conference Call March 27, 2025 9:00 AM ETCompany ParticipantsHenry Wheeler - VP, IR and...
Innate Pharma S.A. 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by Innate Pharma S.A.
Innate Pharma reports FY results

Innate Pharma Reports Full Year 2024 Financial Results and Business Update
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the y...

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its nov...

Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.